Karol K LaCroix

Title: Karol K. LaCroix and Pharmaceutical Compositions of Uridine Triphosphate.

Introduction

Karol K. LaCroix is an inventor associated with Holly Springs, North Carolina, and Inspire Pharmaceuticals, Inc. Her work includes a patent concerning pharmaceutical formulations of uridine 5′-triphosphate (UTP), a compound investigated for promoting mucociliary clearance in the airways, middle and inner ears, and sinuses.

Latest Patents

LaCroix is associated with 1 patent, titled “Pharmaceutical Compositions of Uridine Triphosphate.” The patent describes two formulations intended to help clear retained mucus secretions.

Formulation I combines UTP with an aqueous solution at a therapeutic concentration of 5 to 45 mg/mL. It specifies controlled tonicity, a pH between 7.0 and 7.5, and sterility. The composition is designed for refrigerated storage, with a stated shelf life of up to 30 months, and may be administered as a nebulized or liquid formulation.

Formulation II describes a concentrated UTP solution or suspension, with a concentration approaching the compound’s solubility limit at ambient temperature. Its high concentration is intended to enable delivery in small volumes of 50 to 100 microliters using portable devices, such as metered-dose inhalers. The patent also describes extended shelf life without refrigeration after dispensing to the patient.

Career Highlights

LaCroix’s listed patent work is connected to Inspire Pharmaceuticals, Inc. The disclosed formulations address different delivery needs, including nebulized or liquid administration and small-volume delivery through portable devices.

Collaborations

Janet L. Rideout and Karla M. Jacobus are identified as LaCroix’s coworkers. The available information does not specify their roles in the patent or the development of its formulations.

Conclusion

Karol K. LaCroix’s patent describes two UTP formulations designed to support mucociliary clearance through distinct approaches to concentration, storage, and administration.